NEW YORK (GenomeWeb News) - Nanogen yesterday said third-quarter revenues rose 11 percent as R&D spending rose 16 percent and the company cut its net loss by 36 percent.
 
Total receipts for the three months ended Sept. 30 rose to $8.4 million from $7.5 million year over year.
 
The company said product-related revenue increased 17 percent to $5.5 million from $4.7 million, and income from licensing and royalties slipped 2 percent to $1.8 million from $1.9 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.